MARKET

SGMO

SGMO

SANGAMO THERAPEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.75
-0.01
-0.09%
Closed 17:31 06/14 EDT
OPEN
11.76
PREV CLOSE
11.76
HIGH
11.85
LOW
11.62
VOLUME
1.03M
TURNOVER
--
52 WEEK HIGH
19.43
52 WEEK LOW
8.51
MARKET CAP
1.69B
P/E (TTM)
-13.3934
1D
5D
1M
3M
1Y
5Y
RBC Capital: 3 Stocks to Buy With Over 50% Upside Potential
When investors are looking for fresh investment ideas, recent recommendations from Wall Street analysts can underscore compelling investment opportunities. This is where RBC Capital comes in. The investment firm has issued recommendations on 3 stocks, high...
TipRanks · 18h ago
Did You Miss Sangamo Therapeutics' (NASDAQ:SGMO) 69% Share Price Gain?
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see...
Simply Wall St. · 06/07 14:22
BioMarin (BMRN) Hemophilia Gene Therapy Gets EMA's Speedy Review
Zacks.com · 05/25 14:49
Sangamo Therapeutics names Prathyusha Duraibabu as CFO
Sangamo Therapeutics (SGMO) announces the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021.Ms. Duraibabu joined Sangamo in March 2019 and
Seekingalpha · 05/25 04:20
BRIEF-Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, To CFO
reuters.com · 05/24 21:04
Sangamo Therapeutics Names Prathyusha Duraibabu As CFO
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms.
Benzinga · 05/24 20:16
Sangamo Therapeutics Promotes Prathyusha Duraibabu to CFO
MT Newswires · 05/24 16:36
Sangamo Therapeutics Announces Participation at Jefferies Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 4th at 11am Eastern Time.
Business Wire · 05/21 12:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SGMO. Analyze the recent business situations of SANGAMO THERAPEU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SGMO stock price target is 20.10 with a high estimate of 30.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 299
Institutional Holdings: 86.13M
% Owned: 59.86%
Shares Outstanding: 143.88M
TypeInstitutionsShares
Increased
63
6.83M
New
20
1.81M
Decreased
72
5.57M
Sold Out
37
1.84M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.10%
Pharmaceuticals & Medical Research
+0.13%
Key Executives
Non-Executive Chairman/Independent Director
H. Stewart Parker
President/Chief Executive Officer/Director
Alexander Macrae
Chief Financial Officer/Senior Vice President
Prathyusha Duraibabu
Chief Financial Officer
Prathyusha Durabaibu
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Gary Loeb
Executive Vice President
D. Mark McClung
Executive Vice President
R. Andrew Ramelmeier
Senior Vice President
Rob Schott
Senior Vice President/Chief Scientific Officer
Jason Fontenot
Senior Vice President
Robert Schott
Independent Director
Robert Carey
Independent Director
Kenneth Hillan
Independent Director
John Markels
Independent Director
James Meyers
Independent Director
Saira Ramasastry
Independent Director
Karen Smith
Independent Director
Joseph Zakrzewski
No Data
About SGMO
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Webull offers kinds of Sangamo Therapeutics Inc stock information, including NASDAQ:SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.